TACE Combined With Immune Checkpoint Inhibitors for Liver Malignant Tumors

Who May Qualify: - Confirmed diagnosis of HCC by histology/ cytology or clinical criteria - Sign willing to sign a consent form - When screening for age, the age should be ≥ 18 years old - Eligible for TACE treatment - ECOG physical condition score is 0 or 1 - No previous cancer treatment that works throughout the body (like chemotherapy) for HCC, especially immunotherapy - According to the following mRECIST criteria, at least one measurable intrahepatic lesion is suitable for repeated evaluation Who Should NOT Join This Trial: - Have any history of kidney disease or nephrotic syndrome - Evidence of extrahepatic spread (EHS) - Cardiovascular diseases with clinical significance (such as activity), including unstable angina, ≥ grade 2 congestive heart failure, and arrhythmia with poor drug treatment control - Any condition representing a contraindication to TACE as determined by the investigators - Known genetic factors for bleeding or thrombosis; Any previous or current evidence indicating a tendency for bleeding - Individuals who have received immunotherapy (anti PD-1, anti PD-L1, or anti CTLA-4 treatment) - Previously received HAIC (hepatic artery infusion chemotherapy), TACE (hepatic artery chemoembolization), TAE (hepatic artery embolization), or TARE (hepatic artery radiation embolization) - Previously received systemic anti-cancer treatment for HCC ,ICC or liver metastasis. Always talk to your doctor about whether this trial is right for you.